New Prostate Cancer screening algorithm

A new assessment of the multiplex Stockholm 3 (STHLM3) prostate cancer screening algorithm suggests that, compared with current clinical screening, the test can significantly reduce the rate of unnecessary biopsies without compromising the identification of high-risk prostate cancer."We were quite astonished by this result," said Henrik Grönberg, MD, the study's lead investigator.
Applying the STHLM3 algorithm to a cohort of about 56,000 men who had been assessed in regular clinical practice would have resulted in a 55% reduction in prostate biopsies with either benign or low-risk results, reported Dr Grönberg, who is from the Karolinska Institute in Stockholm, Sweden.